Uricosuric Effect of the Angiotensin II Receptor Antagonist Losartan in Heart Transplant Recipients

Transplantation. 1998 Jul 27;66(2):268-71. doi: 10.1097/00007890-199807270-00023.

Abstract

Background: The angiotensin II receptor antagonist losartan is an effective antihypertensive agent with unique uricosuric properties. This study evaluates the uricosuric effects of losartan in 10 hypertensive heart transplant patients with hyperuricemia.

Methods: The patients were randomized to receive losartan 50 mg once daily and enalapril 20 mg once daily for 4 weeks according to a double-blind crossover design. Office blood pressure, plasma uric acid levels, and urinary uric acid excretion were monitored throughout the study.

Results: Plasma uric acid levels decreased significantly after 4 weeks of treatment with losartan (P<0.05) but not with enalapril. On day 1 and after 1 month of treatment, a significant increase in uric acid excretion was observed only with losartan. Significant decreases in office systolic and diastolic blood pressures were obtained with enalapril but not with losartan.

Conclusions: Losartan effectively lowers plasma uric acid levels in hyperuricemic heart transplant patients.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Angiotensin Receptor Antagonists*
  • Cross-Over Studies
  • Double-Blind Method
  • Enalapril / pharmacology
  • Heart Transplantation*
  • Humans
  • Losartan / pharmacology*
  • Male
  • Middle Aged
  • Uric Acid / blood
  • Uricosuric Agents / pharmacology*

Substances

  • Angiotensin Receptor Antagonists
  • Uricosuric Agents
  • Uric Acid
  • Enalapril
  • Losartan